TABLE 1.
Clinical, demographic and pathological data
| Variable | n | (%) |
|---|---|---|
| Age at diagnosis (years) | ||
| < 55 | 363 | (12) |
| 55–59 | 514 | (17) |
| 60–64 | 583 | (19) |
| > 64 | 1596 | (52) |
| Ethnicity | ||
| Asian | 21 | (1) |
| Latino | 34 | (1) |
| African American | 142 | (5) |
| Caucasian | 2822 | (92) |
| Unknown/other | 37 | (1) |
| Education | ||
| High school | 269 | (9) |
| High school degree | 680 | (22) |
| College | 555 | (18) |
| College degree | 1248 | (41) |
| Missing | 304 | (10) |
| PSA level (ng/mL) | ||
| ≤ 4 | 515 | (17) |
| 4.1–10 | 1943 | (64) |
| 10.1–20 | 364 | (12) |
| > 20 | 133 | (4) |
| Missing | 101 | (3) |
| Biopsy Gleason score | ||
| ≤ 6 | 2043 | (67) |
| 7 | 776 | (25) |
| ≥ 8 | 198 | (6) |
| Missing | 39 | (1) |
| CAPRA risk group | ||
| Low (0–2) | 1804 | (59) |
| Intermediate (3–5) | 956 | (31) |
| High (6–10) | 266 | (9) |
| Missing | 30 | (1) |
| Primary treatment | ||
| RP | 1927 | (63) |
| RT | 843 | (28) |
| PADT | 286 | (9) |
| Neoadjuvant treatment | ||
| No | 2312 | (76) |
| Yes | 744 | (24) |
| Pathological Gleason score (RP only) | ||
| ≤ 6 | 1024 | (53) |
| 7 | 745 | (39) |
| ≥ 8 | 106 | (6) |
CAPRA, Cancer of the Prostate Risk Assessment; PADT, primary androgen deprivation therapy; RP, radical prostatectomy; RT, radiation therapy.